PET basierte neoadjuvante Chemotherapie beim Adenokarzinom des gastroösophgealen Übergangs Typ I und II (MUNICON I): der VEGF 936C>T Polymorphismus ist prädiktiv für die Prognose

The MUNICON I trial confirmed prospectively the usefulness of early response evaluation by FDGPET and showed the feasibility of a PET guided treatment algorithm. Metabolic responders (R) showed initially a higher FDG-uptake compared to nonresponders (NR) (p = 0.018). An association of the VEGF 936C > T polymorphism and FDG-uptake was reported for breast cancer. Therefore we investigated the VEGF 936C > T polymorphism for an association with response and survival.